Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 4/20 | 0.37 |
| ▸ | MTOR | P42345 | 4/20 | 0.37 |
| ▸ | NTRK1 | P04629 | 12/20 | 0.37 |
| ▸ | SPR | P35270 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | KDM5A | P29375 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11027419 | 0.88 | PIK3CA (0.40) | PIK3CAMTORNTRK1 | |
| SCHEMBL2838857 | 0.84 | PIK3CA (0.38) | PIK3CAMTORNTRK1 | |
| SCHEMBL7890083 | 0.82 | SPR (0.36) | NTRK1SPRSMYD3DPP4 | |
| SCHEMBL11026244 | 0.80 | PIK3CA (0.40) | PIK3CAMTORSPR | |
| SCHEMBL755677 | 0.66 | ALDH1A1 (0.31) | PIK3CAMTOR | |
| SCHEMBL754936 | 0.66 | L3MBTL1 (0.33) | PIK3CAMTOR | |
| SCHEMBL11028687 | 0.60 | PIK3CA (0.48) | PIK3CAMTOR | |
| SCHEMBL25405241 | 0.60 | ALDH1A1 (0.52) | SMYD3 | |
| SCHEMBL11030618 | 0.59 | MAPKAPK2 (0.43) | — | |
| SCHEMBL4043347 | 0.59 | ALOX15 (0.51) | SMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | claimed |
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | AMGEN INC. (US) | 2012-07-26 | — | — | US | disclosed |
| EP-2430013-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | Amgen, Inc (US) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010132598-A1 | HETEROARYL COMPOUNDS AS PIKK INHIBITORS | AMGEN INC. (US) | 2010-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190666-A1 | Heteroaryl Compounds as PIKK Inhibitors | PIK3CA, PIKFYVE, PIK3CD | PIK3CA 1/4885MTOR 21/4885NTRK1 939/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.